1:5 Stock Split: Chemical stock hits 5% upper circuit after board approves share split

Synopsis:
Titan Biotech Limited approved a 1:5 stock split, reducing the face value of each share from ₹10 to ₹2, increasing the total number of equity shares.

This Chemical stock, engaged in manufacturing and exporting biological products like protein hydrolysates, peptones, extracts, culture media, food and feed ingredients, hit a 5 percent upper circuit after the company board approved a share split of 1:5.

With a market capitalization of Rs. 830.50 crores, the shares of Titan Biotech Limited hit a 5 percent upper circuit of Rs. 1028.45 per share on Monday, up from its previous closing price of Rs. 979.50 per share. Since then, the stock has retreated and is currently trading at Rs. 1005 per equity share. 

What is the news?

Titan Biotech Limited’s Board of Directors has decided to issue Stock Split shares at a ratio of 1:5, meaning that each equity share’s face value of Rs. 10 will be divided into five equity shares face value of Rs. 2 each.

For example, if a shareholder owns 100 shares valued at Rs. 10 each in Titan Biotech Limited, after the 1:5 stock split, their total holding will increase to 500 shares face value of Rs. 2 each. The value of the holding will remain unchanged.

Company Overview

Titan Biotech Limited was established in 1992 and manufactures and exports specialised biological raw materials and ingredients. It supplies these inputs mainly to pharmaceutical, nutraceutical, food and beverages, biotechnology, fermentation, cosmetic, veterinary and agriculture-related industries in India and overseas.

The company is engaged in producing a wide range of biological products that support the growth of microorganisms and are used in applications like vaccine production, clinical diagnostics, antibiotics, agro‑biotechnology, animal feed and plant sciences. 

Titan Biotech Limited’s offerings include protein hydrolysates, peptones, yeast and liver extracts, malt extract, bile extracts, dehydrated culture media, laboratory chemicals, plant tissue culture media, plant growth promoters, food additives and other speciality ingredients.

Recent quarter results

Coming into financial highlights, Titan Biotech Limited’s revenue has increased from Rs. 39.89 crore in Q2 FY25 to Rs. 54.35 crore in Q2 FY26, which has grown by 36.25 percent. The net profit has also grown by 15.82 percent from Rs. 6.70 crore in Q2 FY25 to Rs. 7.76 crore in Q2 FY26. Titan Biotech Limited’s revenue and net profit have grown at a CAGR of 14.58 percent and 22.42 percent, respectively, over the last five years.

In terms of return ratios, the company’s ROCE and ROE stand at 16.9 percent and 15 percent, respectively. Titan Biotech Limited has an earnings per share (EPS) of Rs. 27.9, and its debt-to-equity ratio is 0.05x.

Written By – Nikhil Naik

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post 1:5 Stock Split: Chemical stock hits 5% upper circuit after board approves share split appeared first on Trade Brains.